ABSTRACT DOUBLE HELIX DESIGN

View On IC.GC.CA

REGISTERED

on 11 Oct 2023

Last Applicant/ Owned by

SAREPTA THERAPEUTICS INC.

215 First StreetCambridge MA 02142

Serial Number

1998138 filed on 7^th Aug 2019

Registration Number

TMA1202272 registered on 11^th Oct 2023

Registration expiry Date

7^th Aug 2029

Correspondent Address

SMART & BIGGAR LP

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOTTAWA

ONTARIO

K1P5Y6

ABSTRACT DOUBLE HELIX DESIGN

Trademark usage description

pharmaceutical preparations, namely, oligonucleotide compounds, gene transfer therapy preparations, and gene editing therapy preparations for use in t Read More

Vienna Information

1 . 13 . 1

Armillary spheres, planetaria, astronomic orbits, atomic models, molecular modelsSphères armillaires, planétariums, orbites astronomiques, schémas d'atomes, schémas de molécules

1 . 13 . 15

Atomic models, molecular models, representations of human, animal or vegetal cells, images of bacteria or viruses, DNA helixesSchémas atomiques, schémas de molécules, représentations de cellules humaines, animales ou végétales, images de bactéries ou de virus, hélices d'ADN

24 . 13 . 9

Crosses formed by intersecting linesCroix formées de lignes qui se coupent

24 . 13 . 25

Other crossesAutres croix

26 . 11 . 13

Wavy lines or bands, zigzag lines or bandsLignes ou bandes ondulées, en dents de scie

26 . 11 . 3

More than two lines or two bandsPlus de deux lignes ou de deux bandes

26 . 11 . 9

Oblique lines or bandsLignes ou bandes obliques

26 . 11 . 7

Vertical lines or bandsLignes ou bandes verticales

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 21

One letterUne lettre

Classification Information

Class [005]
Pharmaceutical preparations, namely, oligonucleotide compounds, gene transfer therapy preparations, and gene editing therapy preparations for use in targeted pharmaceutical therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, for treating loss of neurons, loss of nerves, muscle degeneration, and muscle weakness associated with neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; gene therapy products, namely, gene delivery agents in the form of fluids used for the delivery of pharmaceuticals preparations; pharmaceutical preparations for gene transfer therapy, gene editing, and genome editing; gene therapy products in the nature of injectable biologic preparations for treating loss of neurons, loss of nerves, muscle degeneration, and muscle weakness associated with neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; biological preparations for use in gene therapy containing genetic materials for protein expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; viruses, viral vectors and viral constructs for at least one of regulating, modifying and restricting protein expression for therapeutic purposes for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders

Classification kind code

Mark Details

Serial Number

1998138

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 236 on 18^th Aug 2021	Partial Withdrawal - Madrid Protocol
Submitted for opposition 22 on 8^th Mar 2021	Search Recorded
Submitted for opposition 20 on 8^th Mar 2021	Examiner's First Report
Submitted for opposition 223 on 8^th Mar 2021	Total Provisional Refusal
Submitted for opposition 256 on 28^th Sept 2020	Notification of Possible Opposition Sent
Submitted for opposition 257 on 28^th Nov 2019	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 28^th Nov 2019	Formalized
Submitted for opposition 1 on 28^th Nov 2019	Created
Submitted for opposition 228 on 7^th Aug 2019	International Registration
Submitted for opposition 30 on 7^th Aug 2019	Filed